Response to Comments: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer

This notice documents administrative actions related to MolDX LCD DL39005/L39005: the public comment period ran from 2021-05-20 to 2021-07-03, the notice period began 2022-06-23, and the LCD became effective 2022-08-08; the LCD title was revised to include the word 'Molecular.' The document reports that provider comments were received but does not specify changes to clinical coverage criteria in this notice.

"Comment period for MolDX LCD DL39005 ran from 2021-05-20 through 2021-07-03."

Sign up to see full coverage criteria, indications, and limitations.